KR20040053177A - 유효 용량의 메트포르민과 유효 용량의 글리벤클라미드를함유하는 경구투여용 단일 고형 제제를 포함하는 약학조성물 - Google Patents

유효 용량의 메트포르민과 유효 용량의 글리벤클라미드를함유하는 경구투여용 단일 고형 제제를 포함하는 약학조성물 Download PDF

Info

Publication number
KR20040053177A
KR20040053177A KR10-2004-7005583A KR20047005583A KR20040053177A KR 20040053177 A KR20040053177 A KR 20040053177A KR 20047005583 A KR20047005583 A KR 20047005583A KR 20040053177 A KR20040053177 A KR 20040053177A
Authority
KR
South Korea
Prior art keywords
oral administration
glybenclamide
metformin
pharmaceutical composition
single solid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR10-2004-7005583A
Other languages
English (en)
Korean (ko)
Inventor
이베 봉옴므
제프리 니콜슨
질리언 케이브
사라 제이 니콜슨
Original Assignee
리파
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8235441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20040053177(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 리파 filed Critical 리파
Publication of KR20040053177A publication Critical patent/KR20040053177A/ko
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR10-2004-7005583A 1998-07-15 1999-07-12 유효 용량의 메트포르민과 유효 용량의 글리벤클라미드를함유하는 경구투여용 단일 고형 제제를 포함하는 약학조성물 Ceased KR20040053177A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98401781.4 1998-07-15
EP98401781A EP0974356B1 (en) 1998-07-15 1998-07-15 Tablets comprising a combination of metformin and glibenclamide
PCT/EP1999/005571 WO2000003742A2 (en) 1998-07-15 1999-07-12 Solid oral dosage form comprising a combination of metformin and glibenclamide

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR10-2000-7002714A Division KR100478347B1 (ko) 1998-07-15 1999-07-12 메트포르민과 글리벤클라미드의 배합물을 포함하는 경구투여용 고형 제제

Publications (1)

Publication Number Publication Date
KR20040053177A true KR20040053177A (ko) 2004-06-23

Family

ID=8235441

Family Applications (2)

Application Number Title Priority Date Filing Date
KR10-2004-7005583A Ceased KR20040053177A (ko) 1998-07-15 1999-07-12 유효 용량의 메트포르민과 유효 용량의 글리벤클라미드를함유하는 경구투여용 단일 고형 제제를 포함하는 약학조성물
KR10-2000-7002714A Expired - Lifetime KR100478347B1 (ko) 1998-07-15 1999-07-12 메트포르민과 글리벤클라미드의 배합물을 포함하는 경구투여용 고형 제제

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR10-2000-7002714A Expired - Lifetime KR100478347B1 (ko) 1998-07-15 1999-07-12 메트포르민과 글리벤클라미드의 배합물을 포함하는 경구투여용 고형 제제

Country Status (27)

Country Link
US (2) US6303146B1 (https=)
EP (4) EP0974356B1 (https=)
JP (2) JP2002520371A (https=)
KR (2) KR20040053177A (https=)
CN (2) CN1146427C (https=)
AP (1) AP1450A (https=)
AR (2) AR013052A1 (https=)
AT (1) ATE250418T1 (https=)
AU (2) AU753604B2 (https=)
BR (1) BR9906600A (https=)
CA (1) CA2303537C (https=)
DE (1) DE69818444T2 (https=)
DK (1) DK0974356T3 (https=)
DZ (1) DZ2846A1 (https=)
ES (1) ES2206868T3 (https=)
ID (1) ID25784A (https=)
MA (1) MA24930A1 (https=)
MY (1) MY129552A (https=)
NZ (1) NZ503248A (https=)
OA (1) OA11400A (https=)
PT (1) PT974356E (https=)
RU (2) RU2226396C2 (https=)
SI (1) SI0974356T1 (https=)
TW (2) TWI245632B (https=)
UY (1) UY25611A1 (https=)
WO (1) WO2000003742A2 (https=)
ZA (1) ZA200001159B (https=)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
CA2389928C (en) * 1999-11-03 2010-03-23 Bristol-Myers Squibb Company Method for treating diabetes
US6586438B2 (en) 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2816841B1 (fr) * 2000-11-22 2004-02-06 Lipha Nouvelles compositions pharmaceutiques a action antidiabetique et leur procede de preparation
ATE508738T1 (de) * 2001-01-12 2011-05-15 Sun Pharma Advanced Res Co Ltd System zur beabstandeten abgabe von arzneimitteln
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
US7879869B2 (en) 2001-07-30 2011-02-01 Mitsubishi Tanabe Pharma Corporation Drugs for ameliorating postcibal hyperglycemia
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
ATE361065T1 (de) * 2002-01-25 2007-05-15 Silanes Sa De Cv Lab Pharmazeutische zusammensetzung zur kontrolle des blutzuckers bei patienten mit typ 2 diabetes
CA2476201C (en) * 2002-02-21 2009-09-01 Biovail Laboratories Incorporated Modified release formulations of at least one form of tramadol
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US20030219482A1 (en) * 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
KR20050005437A (ko) 2002-04-09 2005-01-13 플라멜 테크놀로지스 아목시실린의 변형 방출을 위한 마이크로캡슐 수성 현탁액형태의 경구 제약학적 제제
WO2003105809A1 (en) 2002-06-17 2003-12-24 Themis Laboratories Private Limited Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them
US7445796B2 (en) * 2002-08-19 2008-11-04 L. Perrigo Company Pharmaceutically active particles of a monomodal particle size distribution and method
WO2004045622A1 (en) * 2002-11-15 2004-06-03 Ranbaxy Laboratories Limited Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
FR2853831A1 (fr) * 2003-03-05 2004-10-22 Usv Ltd Forme posologique solide a usage oral de metformine et de glyburide et son procede de preparation
CN1780642A (zh) * 2003-04-15 2006-05-31 中外制药株式会社 糖尿病治疗剂
US20060121108A1 (en) * 2004-12-02 2006-06-08 Prasad C K System and method for producing a directly compressible, high-potency formulation of metformin hydrochloride
CN100341495C (zh) * 2004-12-29 2007-10-10 三九医药股份有限公司 格列本脲固体分散体、口服组合物及其制备方法
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
PE20061245A1 (es) * 2005-03-30 2007-01-06 Generex Pharm Inc Composiciones para la transmision transmucosa oral de la metformina
US8529537B2 (en) * 2005-08-05 2013-09-10 Kimberly-Clark Worldwide, Inc. Absorbent article with enclosures
MXPA05009633A (es) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
EP2452683A3 (en) 2006-06-26 2012-08-22 Amgen Inc. Methods for treating atherosclerosis
WO2008062273A2 (en) * 2006-11-20 2008-05-29 Cadila Pharmaceuticals Limited Solid oral dosage form having antidiabetic drug combination
CN101801351B (zh) 2007-07-19 2012-12-12 武田药品工业株式会社 包含阿格列汀和盐酸二甲双胍的固体制剂
ES2559353T3 (es) 2007-07-26 2016-02-11 Amgen, Inc Enzimas lecitina-colesterol aciltransferasa modificadas
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
US20130108699A1 (en) * 2010-04-26 2013-05-02 Jose Antonio Matji Tuduri Highly dispersible granulate for the preparation of formulations of high dosage active substances and procedure for obtaining high dosage active substances thereof
RU2451506C1 (ru) 2011-06-02 2012-05-27 Сергей Юрьевич Лешков Комбинация для лечения сахарного диабета и его осложнений
CA2858572C (en) 2011-12-08 2023-01-17 Amgen Inc. Human lcat antigen binding proteins and their use in therapy
WO2013090452A1 (en) * 2011-12-12 2013-06-20 Orbis Biosciences, Inc. Sustained release particle formulations
CN104127424A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列本脲衍生物及其制备方法和应用
CN105030793A (zh) * 2015-08-25 2015-11-11 瑞阳制药有限公司 二甲双胍格列本脲胶囊及其制备方法
WO2019070109A1 (es) * 2017-10-03 2019-04-11 Infinite Clinical Research International, S.A. De C.V. Triconjugado para el tratamiento de diabetes mellitus
US12459954B2 (en) 2020-04-01 2025-11-04 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Crystalline form a of GLP-1 receptor agonist and preparation method therefor
WO2021196951A1 (zh) 2020-04-01 2021-10-07 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
KR102484756B1 (ko) * 2020-11-13 2023-01-06 한국생산기술연구원 용해성 증대 및 취급용이성을 갖는 파우더 배지의 과립화 방법
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE362704C (de) * 1921-08-09 1922-11-02 Naamlooze Vennootschap Interna Vorrichtung zum Senken einer Last, insbesondere eines Rettungsbootes
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US4060634A (en) * 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
DE2348334C2 (de) 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US4916163A (en) 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
IE63463B1 (en) * 1989-02-06 1995-04-19 Zeneca Ltd Phenylsulphone derivatives
GB9016978D0 (en) * 1990-08-02 1990-09-19 Ici Plc Acetamide derivatives
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE4323636A1 (de) 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
ATE355840T1 (de) 1997-06-18 2007-03-15 Smithkline Beecham Plc Behandlung der diabetes mit thiazolidindione und metformin
US6544564B1 (en) * 2001-11-27 2003-04-08 Michael Donald Farley Cytotoxic pharmaceutical composition

Also Published As

Publication number Publication date
ZA200001159B (en) 2001-05-31
CN1486698A (zh) 2004-04-07
RU2226396C2 (ru) 2004-04-10
MY129552A (en) 2007-04-30
JP2003292443A (ja) 2003-10-15
WO2000003742A2 (en) 2000-01-27
AU5417999A (en) 2000-02-07
EP1435240A2 (en) 2004-07-07
AR013052A1 (es) 2000-11-22
EP0974356B1 (en) 2003-09-24
DE69818444D1 (de) 2003-10-30
UY25611A1 (es) 2000-08-21
PT974356E (pt) 2004-02-27
WO2000003742A3 (en) 2000-04-20
ID25784A (id) 2000-11-02
ES2206868T3 (es) 2004-05-16
TW200303208A (en) 2003-09-01
DK0974356T3 (da) 2003-10-27
NZ503248A (en) 2002-09-27
CN1146427C (zh) 2004-04-21
EP1011684A2 (en) 2000-06-28
JP2002520371A (ja) 2002-07-09
AU2003261560A1 (en) 2005-05-26
OA11400A (en) 2004-04-08
EP2269613A2 (en) 2011-01-05
CA2303537C (en) 2005-12-06
DZ2846A1 (fr) 2003-12-01
EP2269613A3 (en) 2012-10-17
TW555560B (en) 2003-10-01
AU753604B2 (en) 2002-10-24
CN1275082A (zh) 2000-11-29
US6303146B1 (en) 2001-10-16
ATE250418T1 (de) 2003-10-15
KR20010030603A (ko) 2001-04-16
AP1450A (en) 2005-07-25
MA24930A1 (fr) 2000-04-01
EP0974356A1 (en) 2000-01-26
DE69818444T2 (de) 2004-05-06
AP2000001757A0 (en) 2000-03-31
EP1435240A3 (en) 2009-08-12
SI0974356T1 (en) 2003-12-31
RU2286788C2 (ru) 2006-11-10
AR065970A2 (es) 2009-07-15
BR9906600A (pt) 2000-07-18
CA2303537A1 (en) 2000-01-27
USRE38629E1 (en) 2004-10-19
KR100478347B1 (ko) 2005-03-23
RU2003126257A (ru) 2005-02-27
TWI245632B (en) 2005-12-21

Similar Documents

Publication Publication Date Title
KR100478347B1 (ko) 메트포르민과 글리벤클라미드의 배합물을 포함하는 경구투여용 고형 제제
CA2483199C (en) High drug load tablet of imatinib
RU2207856C2 (ru) Способ лечения сердечно-сосудистых заболеваний
US20030187074A1 (en) Oral compositions for treatment of diabetes
KR20040079898A (ko) 메트포르민 및 글리벤클라미드를 포함하는 제 2형 당뇨병치료용 약제학적 조성물
US20060002998A1 (en) Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
US20030224046A1 (en) Unit-dose combination composition for the simultaneous delivery of a short-acting and a long-acting oral hypoglycemic agent
US20040147564A1 (en) Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
WO2006109175A2 (en) Solid dosage form of an antidiabetic drug
WO2004069229A1 (en) Dual release anti-diabetic drugs and process of production thereof
MXPA00002568A (en) Solid oral dosage form comprising a combination of metformin and glibenclamide
WO2004091587A1 (en) Multiple release anti-diabetic drugs and process of production thereof
OA12714A (en) Solid oral dosage form comprising a combination ofmetformin and glibenclamide.

Legal Events

Date Code Title Description
A107 Divisional application of patent
A201 Request for examination
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20040416

PA0201 Request for examination
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20040619

Patent event code: PE09021S01D

PG1501 Laying open of application
AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20050126

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20040619

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20050426

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20050126

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20060721

Appeal identifier: 2005101002583

Request date: 20050426

AMND Amendment
PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20050523

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20050426

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20041118

Patent event code: PB09011R02I

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial
J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20050426

Effective date: 20060721

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20060721

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20050426

Decision date: 20060721

Appeal identifier: 2005101002583